We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Thyroid Nodule Test Could Reduce Unnecessary Surgeries

By HospiMedica staff writers
Posted on 29 May 2008
By testing suspicious thyroid nodules using fine needle aspiration (FNA) for the presence of galectin-3--a lectin molecule that binds specific sugars--a substantial number of unnecessary surgical procedures could be eliminated, claims a new study. More...


Researchers at Sant'Andrea Hospital (Rome, Italy) performed an Italian national study in 465 subjects who had thyroid nodules larger than 1 cm in diameter for which malignancy could not be determined. The subjects enrolled between Jun 1, 2003 and August 30, 2006, were mostly women aged 21 to 76 years, with an average age of 50. The nodules were removed and analyzed with histological testing to determine whether they were cancerous or not. These results were compared to the results of galectin-3 tests.

The results showed that in 71% of the nodules, galectin-3 was not expressed. Of these galectin-3 negative nodules, 85% of them were, as predicted, benign, but 9% were cancerous and thus indicated potential false negatives. Of these, 28% showed different galectin-3 expression when tested post-operatively, suggesting that the false result could have been caused by technical problems in the test. The total sensitivity of the test was 78%, and specificity was 93%. The positive predictive value was 82% and the negative predictive value was 91%. The study was published in the May 19, 2008, issue of The Lancet Oncology.

"The galectin-3 method proposed here does not replace conventional FNA cytology, but represents a complementary diagnostic method for those follicular nodules that remain indeterminate. The correct approach for this preoperative characterization of thyroid nodules always needs careful multidisciplinary assessment of each patient, according to published guidelines,” concluded lead author Armando Bartolazzi, M.D., Ph.D., and colleagues of the department of pathology.

Galectin-3, (Gal-3), a member of the beta-galactoside binding lectin family, is an anti-apoptotic protein that protects T cells, macrophages, and breast carcinoma cells from death triggered by a variety of agents. It is not normally found in the cytoplasm of healthy thyroid cells; if it is abnormally present, it can block cell death, leading to the eventual development of cancer.


Related Links:
Sant'Andrea Hospital

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.